[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 330 4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 67, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 66, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 552017, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Axel  Bolte M.B.A., M.Sc.", "age": 52, "title": "Co-Founder, Senior Advisor & Director", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 40893, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sanjay S. Subramanian M.B.A., M.S.", "age": 48, "title": "CFO, Head of Business Development, Principal Accounting Officer & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 607383, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew  Winton Ph.D.", "age": 46, "title": "Senior VP & COO", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 602100, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Demetrios  Braddock M.D., Ph.D.", "title": "Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yves  Sabbagh Ph.D.", "title": "Senior VP, Chief Scientific Officer & Chair of the Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Riley", "title": "Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gayle  Gironda", "title": "Senior VP & Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Di Palma M.B.A.", "age": 65, "title": "Consultant", "yearBorn": 1959, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kurt C. Gunter FASCP, M.D., Ph.D.", "age": 69, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1955, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.42, "open": 3.94, "dayLow": 3.94, "dayHigh": 3.96, "regularMarketPreviousClose": 1.42, "regularMarketOpen": 3.94, "regularMarketDayLow": 3.94, "regularMarketDayHigh": 3.96, "payoutRatio": 0.0, "beta": 1.345, "forwardPE": -2.4382715, "volume": 49741773, "regularMarketVolume": 49741773, "averageVolume": 817451, "averageVolume10days": 2431890, "averageDailyVolume10Day": 2431890, "bid": 3.94, "ask": 3.99, "bidSize": 99, "askSize": 6, "marketCap": 255019120, "fiftyTwoWeekLow": 0.721, "fiftyTwoWeekHigh": 6.24, "fiftyDayAverage": 1.0498, "twoHundredDayAverage": 2.94635, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 217197200, "profitMargins": 0.0, "floatShares": 36159786, "sharesOutstanding": 64561800, "sharesShort": 3985553, "sharesShortPriorMonth": 4206464, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.0617, "heldPercentInsiders": 0.012259999, "heldPercentInstitutions": 0.83172, "shortRatio": 8.8, "shortPercentOfFloat": 0.066700004, "impliedSharesOutstanding": 64561800, "bookValue": 0.493, "priceToBook": 8.012171, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -106716000, "trailingEps": -1.62, "forwardEps": -1.62, "enterpriseToEbitda": -2.074, "52WeekChange": -0.6997886, "SandP52WeekChange": 0.11469197, "quoteType": "EQUITY", "currentPrice": 3.95, "targetHighPrice": 16.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.83333, "targetMedianPrice": 4.0, "recommendationMean": 2.625, "recommendationKey": "hold", "numberOfAnalystOpinions": 6, "totalCash": 84776000, "totalCashPerShare": 1.313, "ebitda": -104737000, "totalDebt": 46954000, "quickRatio": 1.982, "currentRatio": 2.189, "debtToEquity": 147.663, "returnOnAssets": -0.48452, "returnOnEquity": -1.4168899, "freeCashflow": -56378000, "operatingCashflow": -96523000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "INZY", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Inozyme Pharma, Inc.", "longName": "Inozyme Pharma, Inc.", "regularMarketChangePercent": 178.16904, "regularMarketPrice": 3.95, "postMarketTime": 1747439777, "regularMarketTime": 1747425601, "marketState": "CLOSED", "corporateActions": [], "exchange": "NMS", "messageBoardId": "finmb_568596329", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChange": 2.5300002, "regularMarketDayRange": "3.94 - 3.96", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 817451, "fiftyTwoWeekLowChange": 3.229, "fiftyTwoWeekLowChangePercent": 4.4785023, "fiftyTwoWeekRange": "0.721 - 6.24", "fiftyTwoWeekHighChange": -2.2899997, "fiftyTwoWeekHighChangePercent": -0.36698714, "fiftyTwoWeekChangePercent": -69.97886, "earningsTimestamp": 1747222200, "earningsTimestampStart": 1754310600, "earningsTimestampEnd": 1754656200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.62, "epsForward": -1.62, "epsCurrentYear": -1.24, "priceEpsCurrentYear": -3.185484, "fiftyDayAverageChange": 2.9002, "fiftyDayAverageChangePercent": 2.7626212, "twoHundredDayAverageChange": 1.00365, "twoHundredDayAverageChangePercent": 0.3406418, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-07-24", "averageAnalystRating": "2.6 - Hold", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1595597400000, "postMarketChangePercent": 0.0, "postMarketPrice": 3.95, "postMarketChange": 0.0, "displayName": "Inozyme Pharma", "trailingPegRatio": null, "__fetch_time": "2025-05-17"}]